COVID-19疫苗接种后腋窝淋巴结病的超声评估:一项前瞻性纵向研究
该前瞻性队列研究纳入91例接种COVID-19疫苗后出现腋窝淋巴结病的无症状女性,进行系列超声随访。结果显示淋巴结病常在接种后6周以上持续存在,皮质厚度随时间逐渐减小但mRNA疫苗受者更高。建议结合疫苗类型和接种后时间解读,接种后至少12周随访超声可能合理。
要点
- 接种后腋窝淋巴结病常见持续超过6周,报告需结合接种时间。
- mRNA疫苗受者淋巴结皮质厚度高于载体疫苗受者。
- 对mRNA疫苗受者,接种后至少12周随访超声可能合理。
关键影像表现/征象
- 超声评估皮质厚度、淋巴结数目、形态特征及多普勒信号。
- 随访期间皮质厚度随时间逐渐减小(P < .001),与疫苗类型无关。
- mRNA疫苗受者皮质厚度高于载体疫苗受者(P = .02)。
诊断标准与关键数值
- 完全缓解中位时间6周(范围4-7周),26%(23/88)女性观察到。
- 中位12周(范围8-14周)随访的49例中,51%(25例)淋巴结病持续存在。
临床应用与阅片要点
- 阅片时询问接种疫苗类型及时间,避免误判为转移性淋巴结。
- 对mRNA疫苗受者,接种后12周内出现的腋窝淋巴结病可保守观察。
局限性
- 单中心前瞻性队列,样本量有限(91例),3例失访。
- 仅纳入女性,未包括男性及乳腺癌患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Background Both temporal changes in imaging characteristics of lymphadenopathy on US scans after COVID-19 vaccination and expected duration of radiologically evident lymphadenopathy remain uncertain. Purpose To longitudinally evaluate COVID-19 vaccine-associated lymphadenopathy on axillary US scans at various time intervals in both messenger (mRNA) and vector vaccine recipients. Materials and Methods This prospective cohort study was conducted between March 2021 and January 2022. The participants were asymptomatic women without breast cancer who had received COVID-19 vaccination. Serial follow-up US was performed in women with lymphadenopathy. The following variables were assessed: cortical thickness, number of lymph nodes, morphologic characteristics, and Doppler signal. Temporal changes in cortical thickness and number of lymph nodes during follow-up were assessed using a linear mixed model. Results Ninety-one women with lymphadenopathy in the vaccinated arm had undergone a total of 215 serial US examinations (mean age, 44 years ± 13 [SD]). Fifty-one participants had received a vector vaccine (ChAdOx1 nCoV-19 vaccine) and 40 had received an mRNA vaccine (BNT162b2 vaccine [n = 37] and mRNA-1273 vaccine [n = 3]). Three of the 91 women were lost to follow-up; thus, 88 women underwent serial US. Complete resolution of axillary lymphadenopathy was observed at a median of 6 weeks after vaccination (range, 4-7 weeks) in 26% of women (23 of 88). Among 49 women with follow-up US at a median of 12 weeks after vaccination (range, 8-14 weeks), persistent lymphadenopathy was observed in 25 (51%). During the follow-up period, the cortical thickness gradually decreased (P < .001) over time regardless of vaccine type; however, values were higher in recipients of the mRNA vaccine than in recipients of the vector vaccine (P = .02). Conclusion COVID-19 vaccine-associated axillary lymphadenopathy frequently persisted for more than 6 weeks on US scans. Lymphadenopathy should be interpreted considering vaccine type and time elapsed since vaccination. Follow-up US examination at least 12 weeks after vaccination may be reasonable, particularly for recipients of the messenger RNA vaccine. © RSNA, 2022 Online supplemental material is available for this article. See also the editorial by Moy and Kim in this issue.
引用
- Ha SM, Chu AJ, Lee J, et al. US Evaluation of Axillary Lymphadenopathy Following COVID-19 Vaccination: A Prospective Longitudinal Study. Radiology. 2022. PMID: 35471107. doi:10.1148/radiol.220543
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。